Please assess the completion status of the following clinical trial:

Trial Title: Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects or postmenopausal female subjects aged between 19-70 years~* High risk patients (PROCAM risk ≥20%) on a stable statin-therapy, but at least simvastatin 20 mg/d~* HDL-cholesterol ≤50 mg/dl and /or triglycerides 150-400 mg/dl and/or LDL-cholesterol 70 - 150 mg/dl~* Lipoprotein (a) \< 30 mg/dl~* Patients may have normal glucose metabolism (normal HOMA), be insulin resistant (abnormal HOMA), have impaired fasting glucose or impaired glucose tolerance but not diabetes mellitus.~* Without niacin therapy for at least 6 months~* Dosage of any concomitant medication has been stable for at least 3 weeks~* If female, postmenopausal (absence of menstruation for at least 12 months or absence of menstruation \> 6 months with FSH \> 40 ng/ml respectively oestrogen \< 20 pg/ml)~Exclusion Criteria:~* Subjects with additional causes for hyperlipoproteinemia~* Diabetes mellitus or antidiabetic medication~* Subject has history of cardiovascular ischemia in previous 3 months or acute myocardial infarction or unstable angina~* History of psychiatric disorder or cognitive impairment that would interfere with participation in the study~* History of alcoholism~* Contraindication against niacin and/or laropiprant~* Subject has participated in an investigational study within 30 days prior to study initiation~* Fasting triglycerides \>400 mg/dl~* Life-threatening disease (e.g. cancer)~* Renal insufficiency (GFR ≤ 30 ml/min )~* Major hepatic impairment~* Known allergic reaction/intolerance against niacin and/or laropiprant~* Active peptic ulcer disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Niacin/ Laropiprant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).